Indaptus Therapeutics, Inc. — Investor Relations & Filings

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company that develops immunotherapies for cancer and viral infections. The company's proprietary platform is based on a patented approach that uses engineered, attenuated, and killed non-pathogenic gram-negative bacteria to activate the immune system. This technology, known as Decoy20, is designed to harness the natural ability of bacteria to engage both innate and adaptive immune pathways. By systemically administering these agents, Indaptus aims to stimulate a broad immune response against tumors and virally infected cells. The company's approach has demonstrated anti-tumor and anti-viral activity in pre-clinical models.